文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

急性呼吸窘迫综合征肺保护性通气中正常碳酸血症与轻度高碳酸血症:目标试验模拟

Normocapnia Versus Mild Hypercapnia During Lung Protective Ventilation in Acute Respiratory Distress Syndrome: A Target Trial Emulation.
PubMed 文献 · Crit Care Med · 2026-11-11
一句话结论在接受肺保护性通气的ARDS患者中,通过增加呼吸频率达到正常碳酸血症与轻度高碳酸血症相比,90天院内死亡率无差异(均为28.8%)。

该目标试验模拟纳入ARDS网络与PETAL网络七项随机对照试验中的ARDS患者,1:1模拟分配至正常碳酸血症组(目标PaCO2 35-45 mm Hg)或轻度高碳酸血症组(目标PaCO2 50-55 mm Hg),干预持续4天。每组292例,两组PaCO2分离在4天内维持,pH中位数均≥7.33,驱动压、潮气量、死腔分数无临床显著差异,正常碳酸血症组呼吸频率中位数33.0次/分 vs 轻度高碳酸血症组28.0次/分(p<0.001)。90天院内死亡在正常碳酸血症组84/292例(28.8%),轻度高碳酸血症组84/292例(28.8%)(log-rank p=0.842),在≥65岁和BMI≥30 kg/m2亚组中结果持续。作者结论认为通过增加呼吸频率达到正常碳酸血症与轻度高碳酸血症相比未降低死亡率,但鉴于目标试验模拟存在显著残余偏倚可能,应谨慎解读。

要点

  • 在ARDS肺保护性通气患者中,正常碳酸血症组(目标PaCO2 35-45 mm Hg)与轻度高碳酸血症组(目标PaCO2 50-55 mm Hg)90天院内死亡率均为28.8%(84/292 vs 84/292,log-rank p=0.842)。
  • 正常碳酸血症组呼吸频率中位数33.0次/分,显著高于轻度高碳酸血症组的28.0次/分(p<0.001),两组pH中位数均≥7.33。
  • 两组碳酸氢盐水平、驱动压、潮气量、死腔分数无临床显著差异。
  • 在≥65岁和BMI≥30 kg/m2亚组中,正常碳酸血症与轻度高碳酸血症的死亡率结果持续无差异。
  • 作者结论:通过增加呼吸频率达到正常碳酸血症与轻度高碳酸血症相比未降低死亡率,但目标试验模拟存在显著残余偏倚可能,应谨慎解读。

适用人群与场景

  • 纳入ARDS网络和PETAL网络七项随机对照试验中登记的ARDS患者。
  • 患者接受低潮气量肺保护性通气。

诊断标准与关键阈值

  • 正常碳酸血症组目标PaCO2 35-45 mm Hg,轻度高碳酸血症组目标PaCO2 50-55 mm Hg,干预持续肺保护性通气启动后4天。

研究设计与关键结果

  • 研究设计为目标试验模拟,从5367例潜在合格受试者中1:1分配292例至正常碳酸血症组、292例至轻度高碳酸血症组。
  • 主要终点90天院内死亡:正常碳酸血症组84/292例(28.8%)vs 轻度高碳酸血症组84/292例(28.8%),log-rank p=0.842。
  • 4天干预期间两组PaCO2分离维持,pH中位数均≥7.33。
  • 呼吸频率中位数正常碳酸血症组33.0次/分 vs 轻度高碳酸血症组28.0次/分(p<0.001)。
  • 碳酸氢盐水平、驱动压、潮气量、死腔分数两组间无临床显著差异。
  • 在≥65岁和BMI≥30 kg/m2亚组中死亡率结果持续无差异。

证据类型、等级与局限

  • 证据类型为目标试验模拟。
  • 作者指出该发现源于目标试验模拟,鉴于存在显著残余偏倚可能,应谨慎解读。

对床旁实践的改变

  • 在接受肺保护性通气的ARDS患者中,通过增加呼吸频率达到正常碳酸血症(目标PaCO2 35-45 mm Hg)与轻度高碳酸血症(目标PaCO2 50-55 mm Hg)相比,90天院内死亡率无差异(均为28.8%),作者认为该结果应谨慎解读。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: This trial emulation aimed to answer the question: Among patients with acute respiratory distress syndrome (ARDS) who receive lung protective ventilation with low tidal volume, is normocapnia through an increase in respiratory rate associated with lower mortality than mild hypercapnia?

DESIGN: Target trial emulation.

SETTING: Hospitals of the ARDS Network and Prevention and Early Treatment of Acute Lung Injury (PETAL) Network.

PATIENTS: Patients with ARDS enrolled in seven ARDS Network and PETAL Network randomized controlled trials.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: A target trial was emulated, assigning participants in a 1:1 ratio to normocapnia (target Paco2 35-45 mm Hg) or mild hypercapnia (target Paco2 50-55 mm Hg) for 4 days following the initiation of lung protective ventilation. The primary outcome was 90-day in-hospital mortality. Of 5367 potentially eligible subjects, 292 patients were assigned to normocapnia and 292 to mild hypercapnia. Separation in Paco2 values was preserved over the 4-day period of emulated intervention. Both groups had median pH greater than or equal to 7.33. Bicarbonate levels, driving pressure, tidal volume, and dead-space fraction did not differ clinically significantly between groups, while median respiratory rate was 33.0 breaths/min in the normocapnia vs. 28.0 breaths/min in the mild hypercapnia group (p < 0.001). Death within 90 days occurred in 84 of 292 patients (28.8%) in the normocapnia group and in 84 of 292 patients (28.8%) in the mild hypercapnia group (log-rank p = 0.842). This result persisted in subgroups such as older (≥ 65 yr) and obese (body mass index ≥ 30 kg/m2) patients.

CONCLUSIONS: Among patients with ARDS who received lung protective ventilation, normocapnia through an increase in respiratory rate was not associated with lower mortality than mild hypercapnia. As this finding is derived from a trial emulation, it should be interpreted cautiously given the potential for significant residual bias.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Giannakoulis VG, Papoutsi E, Gkirgkiris K, et al. Normocapnia Versus Mild Hypercapnia During Lung Protective Ventilation in Acute Respiratory Distress Syndrome: A Target Trial Emulation. Crit Care Med. 2026. PMID: 43012617. doi:10.1097/CCM.0000000000007434

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。